Cargando…
Advances in MUC1-Mediated Breast Cancer Immunotherapy
Breast cancer (BRCA) is the leading cause of death from malignant tumors among women. Fortunately, however, immunotherapy has recently become a prospective BRCA treatment with encouraging achievements and mild safety profiles. Since the overexpression and aberrant glycosylation of MUC1 (human mucin)...
Autores principales: | Li, Zhifeng, Yang, Dazhuang, Guo, Ting, Lin, Mei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313386/ https://www.ncbi.nlm.nih.gov/pubmed/35883508 http://dx.doi.org/10.3390/biom12070952 |
Ejemplares similares
-
The Therapeutic Effects of MUC1-C shRNA@Fe(3)O(4) Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer
por: Li, Zhifeng, et al.
Publicado: (2023) -
Latest developments in MUC1 immunotherapy
por: Taylor-Papadimitriou, Joyce, et al.
Publicado: (2018) -
Development of breast cancer immunotherapy using MUC1 retargeted T lymphocytes
por: Wilkie, S, et al.
Publicado: (2006) -
Development of breast cancer immunotherapy using MUC1-retargeted T lymphocytes
por: Wilkie, S, et al.
Publicado: (2008) -
Use of S2.2/DOX Magnetic Nanoliposomes
in MR Molecule Imaging and Targeted Thermochemotherapy for Breast Cancer
In Vitro
por: Zhu, Yinxing, et al.
Publicado: (2023)